

BMJ Open Optimal concentration of ropivacaine for peripheral nerve blocks in adult patients: a protocol for systematic review and meta-analysis

Jing Li,¹ Jiamei Pan,¹ Ying Xu,² Yi Wang,¹ Donghang Zhang,³ Yiyong Wei ⁴

To cite: Li J, Pan J, Xu Y, *et al.* Optimal concentration of ropivacaine for peripheral nerve blocks in adult patients: a protocol for systematic review and meta-analysis. *BMJ Open* 2023;**13**:e077876. doi:10.1136/bmjopen-2023-077876

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2023-077876>).

Received 18 July 2023

Accepted 21 November 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China

²Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China

³Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

⁴Department of Anesthesiology, Longgang District Maternity & Child Healthcare Hospital of Shenzhen City (Longgang Maternity and Child Institute of Shantou University Medical College), Shenzhen, Guangdong, China

Correspondence to

Dr Yiyong Wei;
295502476@qq.com

ABSTRACT

Introduction Ropivacaine is the most widely used local anaesthetic for peripheral nerve blocks (PNBs). The effects of various concentrations of ropivacaine in PNB have been investigated and compared by many randomised controlled trials (RCTs). This protocol aims to identify the optimal concentration of ropivacaine for PNB in adult patients.

Methods and analysis PubMed, EMBASE, the Cochrane library and Web of Science will be searched from their inception to 10 July 2023. RCTs that compare the analgesic effects of different concentrations of ropivacaine for PNB will be included. Retrospective studies, meta-analyses, reviews, case reports, letters, conference abstracts and paediatric studies will be excluded. The duration of analgesia will be named as the primary outcome. Secondary outcomes will include the onset time of motor and sensory blockade, postoperative pain scores, analgesic requirements over 24 hours and the incidence of adverse effects. The study selection, data extraction and quality assessment will be performed by two independent reviewers. Data processing and analysis will be performed by RevMan 5.4. The quality of the evidence will be assessed by the Grading of Recommendations Assessment, Development and Evaluation approach.

Ethics and dissemination Ethical approval is not applicable. The results of this study will be submitted to peer-reviewed journals.

PROSPERO registration number CRD42023406362.

INTRODUCTION

Peripheral nerve blocks (PNBs) are widely used to provide perioperative analgesia for various types of surgeries.^{1–3} In addition to pain relief, PNB can also reduce the consumption of general anaesthetics and/or opioids, decrease the incidence of postoperative complications and improve the recovery quality.^{4–6} Currently, ropivacaine is the most commonly used local anaesthetic for PNB due to its lower toxicity in the central nervous system and heart.^{7 8} The concentrations of ropivacaine used for PNB are various, and the efficacy and safety of different concentrations of ropivacaine have been compared

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Subgroup analysis will be used to explore the heterogeneity resource and provide evidence to guide ropivacaine use in certain surgical types or specific approaches to PNB.
- ⇒ We will use the Grading of Recommendations Assessment, Development and Evaluation approach to assess the quality of evidence for primary outcomes.
- ⇒ Significant heterogeneity may exist among the included randomised controlled trials due to several factors, such as the type of surgery or nerve block, the usage of general anaesthetics, opioids or adjuvants and the volumes of ropivacaine.

in several RCTs,^{9–14} but the results were inconsistent. Therefore, it is meaningful to perform a systematic review and meta-analysis to determine the optimal concentration of ropivacaine for PNB, which may provide longer analgesia without increasing the incidence of adverse effects. Furthermore, we will perform a subgroup analysis to find the recommended ropivacaine concentration for a specific type of nerve block.

METHODS AND ANALYSIS

Study registration

This protocol has been registered in the International Prospective Register of Systematic Reviews (PROSPERO; registration number: CRD42023406362). This study is conducted according to the Preferred Reporting Items for Systematic Evaluation and Meta-Analysis Protocols. Ethical approval is not required.

Search strategy

We will search PubMed, the Cochrane library, EMBASE and the Web of Science from their inception to 10 July 2023, to identify RCTs that compared the analgesic effects of different concentrations of ropivacaine for

Table 1 The search strategy in PubMed

Number	Search terms
#1	Ropivacaine (Mesh)
#2	Ropivacaine (title/abstract)
#3	#1 OR #2
#4	Nerve block (title/abstract)
#5	Nerve blockade (title/abstract)
#6	Peripheral nerve block (title/abstract)
#7	Peripheral nerve blockade (title/abstract)
#8	#4 OR #5 OR #6 OR #7
#9	Randomised controlled trial (title/abstract)
#10	Randomised (title/abstract)
#11	Clinical study (title/abstract)
#12	Clinical trial (title/abstract)
#13	Controlled clinical trial (Title/Abstract)
#14	#9 OR #10 OR #11 OR #12 OR #13
#15	#3 AND #8 AND #14

PNB. The keywords for the search will include 'ropivacaine', 'nerve block' and 'randomised controlled trials'. The language will be restricted to English. The search strategy for PubMed and other databases is presented in [table 1](#) and online supplemental file 1, respectively.

Inclusion and exclusion criteria

Study type: RCTs, participants: adult patients (>18 years) who underwent surgeries with PNB, comparisons: different concentrations of ropivacaine for PNB, primary outcomes: duration of analgesia (time to first analgesic request), secondary outcomes: the onset time of motor and sensory blockade, postoperative pain scores, analgesic requirements over 24 hours, and the incidence of adverse effects (eg, nausea, vomiting, drowsiness, dizziness, itching and constipation). Retrospective studies, meta-analyses, reviews, case reports, letters and conference abstracts will be excluded.

Study selection

Two authors will independently select eligible studies by screening their title, abstract, and full text. The disagreement will be resolved by discussion with a third author. The flowchart for study selection is shown in [figure 1](#).

Data extraction

The following information will be extracted: author, publication year, countries, sample, characteristics of participants, surgical type, type of anaesthesia and nerve blocks, adjuvants, comparisons, outcomes and perioperative analgesia.

Risk of bias assessment

We will assess the risk of bias for included studies using the Cochrane Collaboration tool.¹⁵ Six items will be focused on random sequence generation (selection bias),

allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias) and selective reporting (reporting bias). The estimated results for each item will be graded as 'unclear', 'low' or 'high'.

Statistical analysis

Data analysis will be performed by RevMan 5.4. Continuous data will be summarised using mean differences with 95% CI. Dichotomous data will be summarised by risk ratios (RR) with a 95% CI. Statistical heterogeneity will be assessed by the I^2 test. Data will be synthesised using a fixed-effect model if $I^2 < 50\%$. Significant heterogeneity will be considered to exist when $I^2 > 50\%$, and then a random-effects model will be applied. Subgroup analysis and meta-regression will be further conducted to explore the heterogeneity source. We will also perform a sensitivity analysis to test whether the results are robust and reliable. $p < 0.05$ means statistically significant. The GRADE approach will assess the quality of evidence for each outcome, and the evidence will be rated as 'very low', 'low', 'moderate' or 'high'.

Patient and public involvement

None.

ETHICS AND DISSEMINATION

Ethical approval is not applicable. The results of this study will be submitted to peer-reviewed journals.

DISCUSSION

Ropivacaine is the most commonly used local anaesthetic for PNB due to its lower central nervous system and cardiac toxicity. Currently, the concentration of ropivacaine used for PNB mainly varies from 0.25% to 1%. Emerging RCTs have compared the effects of different concentrations of ropivacaine for PNB, but the optimal concentration remains unclear. This protocol for a systematic review and meta-analysis aims to identify the optimal concentration of ropivacaine for PNB in adult patients. An optimal concentration of ropivacaine will offer longer analgesia but not increase the incidence of adverse effects. However, several limitations should be noticed. First, significant heterogeneity may exist among the included RCTs due to several factors, such as the type of surgery or nerve block, the usage of general anaesthetics, opioids or adjuvants and the volumes of ropivacaine. Second, it should be considered that the definition of the duration of analgesia among studies may be different, which will influence the results. It is better to minimise the heterogeneity by categorising the analgesia duration differently according to their definition in individual studies. Therefore, we will use subgroup analysis and meta-regression to explore the source of heterogeneity. We will also perform a sensitivity analysis to test whether the pooled




Figure 1 The flowchart for study selection.

results are robust and reliable. Another limitation is that the number of studies comparing the effects of different concentrations of ropivacaine for PNB may be relatively small, especially for subgroup analysis. Therefore, well-designed, large-sample RCTs may be needed to determine the optimal concentration of ropivacaine for PNB.

According to our protocol, subgroup analysis will recommend the optimal concentration of ropivacaine for a specific nerve block or general anaesthesia. Additionally, we will use the GRADE approach to assess the quality of evidence for primary outcomes. Therefore, this study may provide evidence to guide the clinical use of ropivacaine for PNB in adult patients.

Contributors Conceptualisation: YW and DZ. Methodology: JL and YW. Validation: JL, JP and YW. Writing original draft: JL, JP, YX, YW and YW. Writing, review and editing: YW and DZ.

Funding This study was supported by Grant No. 2022NSFSC1399 (to Donghang Zhang) from the Natural Science Foundation of Sichuan Province.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Yiyong Wei <http://orcid.org/0000-0002-2754-7204>

REFERENCES

- 1 Hussain N, Brull R, Vannabouathong C, *et al.* Network meta-analysis of the analgesic effectiveness of regional anaesthesia techniques for anterior Cruciate ligament reconstruction. *Anaesthesia* 2023;78:207–24.
- 2 Crutchfield CR, Schweppe EA, Padaki AS, *et al.* A practical guide to lower extremity nerve blocks for the sports medicine surgeon. *Am J Sports Med* 2023;51:279–97.
- 3 Memtsoudis SG, Cozowicz C, Bekeris J, *et al.* Peripheral nerve block anesthesia/analgesia for patients undergoing primary hip and knee Arthroplasty: recommendations from the International consensus on anesthesia-related outcomes after surgery (ICAROS) group based on a systematic review and meta-analysis of current literature. *Reg Anesth Pain Med* 2021;46:971–85.
- 4 Guerra-Londono CE, Privorotskiy A, Cozowicz C, *et al.* Assessment of Intercostal nerve block analgesia for Thoracic surgery: A systematic review and meta-analysis. *JAMA Netw Open* 2021;4:e2133394.
- 5 Grape S, Kirkham KR, Akiki L, *et al.* Transversus abdominis plane block versus local anesthetic wound infiltration for optimal analgesia after Laparoscopic Cholecystectomy: A systematic review and meta-analysis with trial sequential analysis. *J Clin Anesth* 2021;75:110450.
- 6 Ní Eochagáin A, Singleton BN, Moorthy A, *et al.* Regional and neuraxial anaesthesia techniques for spinal surgery: a Scoping review. *British Journal of Anaesthesia* 2022;129:598–611.
- 7 Vainionpää VA, Haavisto ET, Huha TM, *et al.* A clinical and pharmacokinetic comparison of ropivacaine and bupivacaine in Axillary plexus block. *Anesth Analg* 1995;81:534–8.
- 8 McClellan KJ, Faulds D. Ropivacaine: an update of its use in regional anaesthesia. *Drugs* 2000;60:1065–93.
- 9 Klein SM, Greengrass RA, Steele SM, *et al.* A comparison of 0.5% bupivacaine, 0.5% ropivacaine, and 0.75% ropivacaine for interscalene brachial plexus block. *Anesth Analg* 1998;87:1316–9.
- 10 Bertini L, Tagariello V, Mancini S, *et al.* 0.75% and 0.5% ropivacaine for Axillary brachial plexus block: a clinical comparison with 0.5% bupivacaine. *Reg Anesth Pain Med* 1999;24:514–8.
- 11 Casati A, Fanelli G, Aldegheri G, *et al.* Interscalene brachial plexus anaesthesia with 0.5%, 0.75% or 1% ropivacaine: a double-blind comparison with 2% mepivacaine. *Br J Anaesth* 1999;83:872–5.
- 12 Wang S, Fang H, Qin J, *et al.* Comparison of the efficacy of Costoclavicular space brachial plexus blockade with 0.5% versus 0.375% ropivacaine: a randomized, double-blind, single-centre, Noninferiority clinical trial. *Can J Anaesth* 2023;70:106–15.
- 13 Jian C, Shen Y, Fu H, *et al.* Effects of ultrasound-guided Erector Spinae plane block with dexmedetomidine combined with ropivacaine of the same dose and different concentrations on analgesic effect and rehabilitation quality of patients undergoing Thoracoscopic wedge resection of the lung: a prospective, randomized, controlled trial. *BMC Anesthesiol* 2022;22:225.
- 14 Tian Y, Zhan Y, Liu K, *et al.* Analgesic effects of different concentrations of ropivacaine in Transversalis Fascia plane block during Laparotomy. *BMC Anesthesiol* 2022;22:54.
- 15 Higgins J, Green SR. Cochrane Handbook for systematic review of Interventions version 5.1.0. 2011.